Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology

BURLINGAME, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that the company will host and provide a live webcast for its R&D Day, starting at 9:00 AM ET on March 14, 2017 in New York City.  

The event will highlight the emerging role of the adenosine axis in immuno-oncology and its potential to address the limitations of existing agents. Additionally, Corvus will provide updates on its progress in clinical trials evaluating its lead CPI-444 program as well as the company’s pipeline.

Speakers at the event include:

  • Jonathan D. Powell, MD, PhD (Johns Hopkins University)
  • Lawrence Fong, MD (University of California, San Francisco)
  • Richard Miller, MD (Corvus Co-Founder, President and CEO)
R&D Day Webcast and Conference Call Details 
Event Title:    R&D Day Update: The Emergence of the Adenosine Pathway in Cancer Immunotherapy
Date:    Tuesday, March 14, 2017
Time:    9:00 - 12:00 p.m. ET
Webcast:    The live webcast and slide presentation can be accessed at

An archive of the webcast will be available in the Investors section of the company's website for 30 days following the event.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit:

Tecentriq® is a registered trademark of Genentech.

CONTACT: Corvus Contact:
Jason Coloma
SVP, Chief Business Officer  
Corvus Pharmaceuticals, Inc. 

Media Contact:
Julie Normart
Pure Communications